Menumenu
  • Home
  • Musculoskeletal diseases Publications

Musculoskeletal diseases Publications

Musculoskeletal diseases Publications

  • Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.Abstract

    OBJECTIVE: To identify determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. By considering the year of the introduction of weekly bisphosphonates important additional information is obtained. METHODS: New fmale users of daily or weekly alendronate or risedronate between 1999 and 2004, aged >or= 45 years were identified from PHARMO RLS, including drug-dispensing and hospitalisation data of > 2 million residents of the Netherlands

    Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Curr Med Res Opin. 2008 May; 24 (5): 1337-1344.
  • Loss of treatment benefit due to low compliance with bisphosphonate therapy.Abstract

    SUMMARY: Among 8,822 new female bisphosphonate users, non-compliant bisphosphonate use was associated with a 45% increased risk of osteoporotic fracture compared to compliant use (MPR >or=80%). Classifying compliance into five categories, fractureisk gradually increased with poorer compliance. These results emphasize the importance of treatment compliance in obtaining maximal treatment benefit

    Penning-van Beest FJ, Erkens JA, Olson M, Herings RM. Osteoporos Int. 2008 Apr; 19 (4): 511-7.
  • Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures.Abstract

    OBJECTIVES: To investigate the relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures.METHODS: The PHARMO database was used to identify new female bisphosphonate users, aged >/= 45 years or with diagnosd post-menopausal osteoporosis in the period of January 1996 – June 2004

    Meijer WM, Beest FJ, Olson M, Herings RM. Curr Med Res Opin. 2008 Inpress; 24 (11): 3217-3222.
  • Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study.Abstract

    INTRODUCTION: Administration of beta-2 agonists decreased bone mineral density in rats. But the association between bronchodilators and fracture risk has not been studied in humans. OBJECTIVES: To examine the association between use of beta-2 agonits and risk of hip/femur fracture. METHODS: We conducted a population-based case-control study (6763 cases) in the Dutch PHARMO database

    de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW, van Staa TP. Pharmacoepidemiol Drug Saf. 2007 Jun; 16 (6): 612-9.
  • Developments of the incidence of osteoporosis in The Netherlands: a PHARMO study.Abstract

    PURPOSE: To assess recent and to predict future time trends in the incidence of osteoporosis using routine databases in The Netherlands in the period 1993-2015 and to compare estimations based on hip fractures versus a proxy based on pharmacy and hspitalisation data. METHODS: The incidence of hip fractures was estimated over the period 1986-2002 using information from the Dutch Medical Registry, covering more than 99% of all Dutch hospitalisations

    Goettsch WG, de Jong RB, Kramarz P, Herings RM. Pharmacoepidemiol Drug Saf. 2007 Feb; 16 (2): 166-72.
  • Use of beta-Blockers and the Risk of Hip/Femur Fracture in the United Kingdom and The Netherlands.Abstract

    Data from in vivo studies have indicated a role for beta-blockers in the prevention of bone loss. Some epidemiological studies have found protective effects of beta-blockers on fracture risk. However, there is limited information on the associationwith cumulative dose and type of beta-blockers used. We conducted two case-control studies using data from the UK General Practice Research Database (GPRD) and the Dutch PHARMO Record Linkage System (RLS)

    de Vries F, Souverein PC, Cooper C, Leufkens HG, van Staa TP. Calcif Tissue Int. 2007 Feb; 80 (2): 69-75.
  • Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.Abstract

    Patients using higher dosages of inhaled or oral glucocorticoids (GCs) have an increased risk of hip/femur fractures. The role of the underlying disease in the aetiology of this increased risk has not been widely studied. Objective. To evaluate thecontribution of the underlying disease to the risk of hip/femur fracture in patients using inhaled or oral GCs

    de Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C, van Staa TP. J Intern Med. 2007 Feb; 261 (2): 170-7.
  • Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.Abstract

    BACKGROUND: Although bisphosphonates are useful in the management of osteoporosis, patients often discontinue treatment. OBJECTIVES: The aims of this study were to investigate persistence with bisphosphonates, and to assess whether the dose intervainfluenced persistence, among women with postmenopausal osteoporosis

    Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Clin Ther. 2006 Feb; 28 (2): 236-42.
  • Persistent biphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study..Abstract

    van den Boogaard CHA, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RMC. Curr Med Res Opin. 2006 22 (9): 1757-64.